Medscape10h
Trastuzumab Emtansine Ups Long-term Survival in HER2-Positive Breast Cancer
Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...
Phase III trial finds trastuzumab emtansine improves long-term survival in HER2 breast cancer
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...
Hosted on MSN59m
Survival Benefit With Adjuvant T-DM1 in High-Risk HER2-Positive Breast Cancer
Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...
Healio13h
Adjuvant regimen extends survival in early HER2-positive breast cancer
Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...
Govt may propose duty cuts for rare-disease medicines, cancer drugs in budget to ease burden on patients
The landscape of rare diseases is constantly changing as new ailments and conditions are identified and reported regularly.
Oncology Nurse Advisor7d
Pyrotinib Improves Upon Trastuzumab and Docetaxel in HER2+ Metastatic Breast Cancer
Phase 3 data support pyrotinib plus trastuzumab and docetaxel “as a well-established and effective treatment strategy,” according to Binghe Xu, MD.
Pharmaceutical Technology10d
Trastuzumab pamirtecan by BioNTech for Solid Tumor: Likelihood of Approval
Trastuzumab pamirtecan is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...
The 6 signs of ‘hard to spot’ bile duct cancer that kills majority of patients within a year
FOR the 6,000 people in the UK who are newly diagnosed with bile duct cancer every year, the prognosis is uniquely grim.